The government has set a negotiated Medicare price of $274 for a month’s supply of the blockbuster semaglutide drugs sold as Ozempic and Wegovy, a roughly 71 percent cut from the $959 list price they carry today. The new figure takes effect January 1, 2027, and comes out of the second round of price talks Medicare is allowed to hold with drug makers. For the millions of older Americans who take these medicines for diabetes or heart-related conditions, the change reshapes one of the most expensive line items in a Part D drug budget.
How the $274 price was set and what it covers
The price is the product of direct negotiation between Medicare and Novo Nordisk, the manufacturer of semaglutide, under authority Congress granted in 2022. The government’s official schedule of negotiated prices lists $274 as the amount tied to a 30-day equivalent supply, down from a list price near $959. That drop of about 71 percent is among the steepest the program has produced so far, a reflection of how far the sticker price on these drugs had climbed.
The $274 figure applies across the semaglutide family, which is sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight-related conditions. Higher-dose versions of Wegovy carry a separate negotiated price of $385 on the same negotiated-price schedule, so the exact number depends on the specific product and dose a patient is prescribed. In each case the negotiated price replaces the old list price as the baseline Medicare and its drug plans work from starting in 2027.
Semaglutide was one of 15 drugs in this second negotiation round, all with prices taking effect in 2027, but it drew the most attention because of how widely it is prescribed and how far its price had climbed. The other medicines in the same round treat conditions common in older adults, from blood clots to chronic breathing problems, so the semaglutide cut is really the headline of a broader set of reductions arriving on the same January date.
Free retirement updates: Social Security and Medicare change every year, and nobody sends you a memo. Our free Retirement Shield newsletter breaks down what changed and what to do. Get it free in your inbox.
What a patient actually pays is not the same as the price
The negotiated $274 is best understood as a maximum fair price, the ceiling Medicare uses rather than the amount that appears on any single receipt. What a beneficiary personally owes still runs through the ordinary Part D machinery of deductibles, copays, and coverage stages, so two people on the same drug can pay different shares depending on their plan and where they sit in the year. A lower underlying price generally pulls a patient’s out-of-pocket cost down, but it does not set that cost by itself.
Coverage rules also decide whether a plan pays at all. Medicare drug plans cover Ozempic for type 2 diabetes, and since 2024 they have been allowed to cover Wegovy when it is prescribed to reduce cardiovascular risk in certain adults with heart disease, rather than for weight loss on its own. A patient seeking one of these drugs strictly to lose weight may still find it excluded, because federal law bars Part D from covering medications used only for weight reduction.
The interaction with supplemental coverage adds one more variable. A beneficiary who carries retiree drug coverage or another layer on top of Part D may see the negotiated price flow through differently than someone on a standalone plan alone, because those add-ons absorb portions of the cost that would otherwise land squarely on the patient. The negotiated figure sets the baseline, but the layers of coverage stacked around it decide how much of the drop any one person actually keeps.
An annual cap adds another layer of relief that interacts with the lower price. Medicare now limits what a Part D enrollee pays out of pocket for covered drugs across a full year, a ceiling set at $2,000 in 2025 and adjusted upward each year. For someone already hitting that cap on a pricey semaglutide prescription, the negotiated price mainly changes what the plan and the program spend; for those who never reach the cap, the lower baseline can trim the copay directly. Medicare’s guide to drug-plan costs lays out how those stages fit together.
Why this round of cuts reaches so many retirees
Semaglutide sits at the center of the negotiation program precisely because so much Medicare money flows to it. The drugs have become some of the most prescribed and most expensive in the country, and pulling their price down moves a large block of spending in a way that a discount on a niche medicine never could. That concentration is what makes a single negotiated figure matter to a broad slice of the Medicare population.
The reach is widened by how many Medicare beneficiaries live with type 2 diabetes, the condition Ozempic is approved to treat. Diabetes ranks among the most common chronic illnesses in people over 65, and semaglutide has become a mainstay of managing it, which is why a price change on this one drug family touches such a large share of the Medicare rolls rather than a narrow group of patients. The scale of use, not just the size of the discount, is what gives the cut its weight.
The timing still requires patience. The $274 and $385 prices are locked for 2027, not for the current plan year, so a patient filling a semaglutide prescription today continues to pay under the old pricing until the new numbers take effect. Confusing a scheduled 2027 price with a discount available now is the most common misunderstanding around these announcements, as the health-policy group KFF has noted in tracking each cycle.
What remains unsettled is how the savings split between the government and individual patients once plan designs adjust for 2027. The negotiated price is fixed, but drug plans will rework their formularies, tiers, and premiums around it, and the net effect on any one retiree’s bill will not be clear until those 2027 plans are published. For now the certainty is the price itself: a drug that lists near $959 will carry a Medicare-negotiated tag of $274 come January 2027.
This article was produced with AI assistance and reviewed against primary sources by The Money Overview editorial team.
More Financial Reading
